Physician profile
Emily Dimango
NPI 1407933195
$58,733.88
in general payments reported to CMS, 2019-2025
18 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2020: $16K · 2021: $1,300 · 2022: $2,736 · 2023: $5,927 · 2024: $2,109 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,696 · Food and Beverage: $786 · Travel and Lodging: $689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,695.58 |
| Food and Beverage | $786.38 |
| Travel and Lodging | $688.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $26,129.48 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $20,020.89 | 2019-2024 | Airsupra, Fasenra |
| Mylan Specialty L.P. | $4,982.49 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,654.14 | 2022-2023 | |
| Pari Respiratory Equipment, INC. | $1,627.50 | 2019 | |
| Boehringer Ingelheim International Gmbh | $1,445.58 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $1,380.00 | 2019 | |
| Baxter Healthcare | $161.83 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Glaxosmithkline, LLC. | $150.44 | 2022-2025 | Nucala, Trelegy Ellipta |
| Chiesi USA, INC. | $43.40 | 2020-2023 | Bronchitol |
| Philips North America LLC | $28.14 | 2024 | (Ak6) Vest Therapy |
| Regeneron Healthcare Solutions, INC. | $26.06 | 2023 | Dupixent |
| Allergan, INC. | $24.61 | 2019 | |
| Insmed, INC. | $17.19 | 2025 | Arikayce |
| Abbvie INC. | $16.00 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $13.43 | 2023 | |
| Merck Sharp & Dohme LLC | $12.70 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Dimango listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.